The startup raised a US$43-million round in 2025 co-led by the ChatGPT maker and Founders Fund, Peter Thiel’s VC firm, as well as a Founders Fund-led US$22-million round in 2024. In 2023, Biossil raised a $3.7-million seed round led by Staircase Ventures with participation from Golden Ventures and Panache Ventures. (The Globe and Mail)
Talking point: Former tech banker Anthony Mouchantaf and medical doctor Alexander Mosa co-founded Biossil in March 2023. The firm uses large language models to identify drug candidates that failed in clinical trials, then see whether they might have other uses or work in different settings. Biossil buys or licenses the potential medicines from the original maker, then runs new tests to try to take them to market. It’s making its bet further down the drug development process than many other AI-driven firms, which have typically used the technology to help identify molecules that might turn into medicines.
Loading...
You have shared 5 articles this month and reached the maximum amount of shares available.
CloseIf you would like to purchase a sharing license please contact The Logic support at [email protected].
CloseYou have gifted 0 article(s) this month and have 5 remaining.
Recipients will be able to read the full text of the article after submitting their email address. They will not have access to other articles or subscriber benefits.
Get up to speed in minutes with insights and analysis on the most important stories of the day, every weekday.
See the bigger picture with reporters and industry experts in subscriber-exclusive events.
Membership provides access to our popular Slack channel, participation in subscriber surveys and invitations to exclusive events with our journalists and special guests.